PMID- 36016244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 10
IP  - 8
DP  - 2022 Aug 19
TI  - Young Age, Female Sex, and No Comorbidities Are Risk Factors for Adverse 
      Reactions after the Third Dose of BNT162b2 COVID-19 Vaccine against SARS-CoV-2: A 
      Prospective Cohort Study in Japan.
LID - 10.3390/vaccines10081357 [doi]
LID - 1357
AB  - BACKGROUND: This study compared the adverse events (AEs) of the second and third 
      doses of BNT162b2, as well as investigated the impact of vaccine recipients' 
      background and vaccination interval on the AEs of the third dose. METHODS: We 
      conducted a questionnaire survey of AEs among health care workers at Osaka 
      University Dental Hospital. Chi-square tests were performed to compare AEs to the 
      administration of second and third vaccine doses. Logistic regression analyses 
      were conducted to identify factors influencing the presence of AEs using age, 
      sex, comorbidities, and the vaccination interval. Spearman's rank correlation 
      coefficient was calculated to investigate the correlation between age, 
      vaccination interval, and severity of each AE. RESULTS: The third dose of 
      BNT162b2 was associated with significantly more frequent or milder AEs than the 
      second dose. Logistic regression analyses detected significant differences in six 
      items of AEs by age, three by sex, two by comorbidities, and zero by vaccination 
      interval. Consistently, the risk of AEs was greater among younger persons, 
      females, and those without comorbidities. Significant negative correlations were 
      detected between age and vaccination interval, and between age and the severity 
      of most AEs. CONCLUSIONS: Young, female, and having no comorbidities are risk 
      factors for AEs after the third dose of BNT162b2, while vaccination interval is 
      not.
FAU - Urakawa, Ryuta
AU  - Urakawa R
AUID- ORCID: 0000-0003-0412-4118
AD  - Department of Pharmacy, Osaka University Dental Hospital, 1-8 Yamada-oka, Suita 
      565-0871, Osaka, Japan.
AD  - Department of Clinical Pharmacy Research and Education, Graduate School of 
      Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita 565-0871, Osaka, 
      Japan.
FAU - Isomura, Emiko Tanaka
AU  - Isomura ET
AUID- ORCID: 0000-0002-7855-9600
AD  - First Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, 
      Osaka University, 1-8 Yamada-oka, Suita 565-0871, Osaka, Japan.
FAU - Matsunaga, Kazuhide
AU  - Matsunaga K
AD  - Second Department of Oral and Maxillofacial Surgery, Graduate School of 
      Dentistry, Osaka University, 1-8 Yamada-oka, Suita 565-0871, Osaka, Japan.
FAU - Kubota, Kazumi
AU  - Kubota K
AD  - Department of Healthcare Information Management, The University of Tokyo 
      Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220819
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC9416095
OTO - NOTNLM
OT  - adverse event
OT  - booster
OT  - infectious disease
OT  - side effect
OT  - vaccination interval
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2022/08/19
CRDT- 2022/08/26 01:48
PHST- 2022/07/29 00:00 [received]
PHST- 2022/08/15 00:00 [revised]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/08/26 01:48 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2022/08/19 00:00 [pmc-release]
AID - vaccines10081357 [pii]
AID - vaccines-10-01357 [pii]
AID - 10.3390/vaccines10081357 [doi]
PST - epublish
SO  - Vaccines (Basel). 2022 Aug 19;10(8):1357. doi: 10.3390/vaccines10081357.